Depotentiation of associative plasticity is intact in Parkinson's disease with mild dyskinesia

Parkinsonism Relat Disord. 2022 Jun:99:16-22. doi: 10.1016/j.parkreldis.2022.04.019. Epub 2022 May 1.

Abstract

Objective: Depotentiation of homosynaptic plasticity of the primary motor cortex (M1) is impaired in patients with Parkinson's disease (PD) who have developed dyskinesias. In this exploratory study, we tested whether this holds true for heterosynaptic plasticity induced by paired associative stimulation (PAS).

Methods: Dyskinetic (n=11) and Non-dyskinetic (n=11), levodopa-treated PD patients were tested in M1 with PAS25ms alone, PAS25ms preceded by continuous theta-burst stimulation of the cerebellum (cTBSCB-PAS) as a method to evoke a larger plastic response in M1, and each of these two interventions followed by a depotentiation protocol (cTBS150pulses) to M1.

Results: PAS25ms and cTBSCB-PAS25ms induced long-term potentiation (LTP)-like responses in both groups of PD patients, with cTBSCB significantly boosting the plastic response. Both these LTP-like responses could be depotentiated by cTBS150, in both groups of patients.

Conclusions: Cerebellar stimulation enhances heterosynaptic plasticity in PD irrespective of dyskinesias. Depotentiation mechanisms of heterosynaptic plasticity are preserved in PD patients, including those with dyskinesias. The lack of depotentiation of LTP-like plasticity as a hallmark of dyskinesia in PD patients is not absolute. The ability to depotentiate LTP-like plasticity may potentially depend on the type of plasticity induced (homosynaptic or heterosynaptic), the circuits involved in these responses and the adequacy of dopaminergic stimulation.

Keywords: Cerebellum; Depotentiation; Dyskinesia; Levodopa; Long-term potentiation; Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Dyskinesia, Drug-Induced* / etiology
  • Evoked Potentials, Motor / physiology
  • Humans
  • Long-Term Synaptic Depression / physiology
  • Motor Cortex*
  • Neuronal Plasticity
  • Parkinson Disease* / complications
  • Transcranial Magnetic Stimulation / methods

Substances

  • Antiparkinson Agents